Bio
Guido Kroemer is currently Professor at the Faculty of Medicine of the University of Paris Descartes, Director of the research team "Apoptosis, Cancer and Immunity" of the French…
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Autophagy is required for the therapeutic effects of the NAD+ precursor nicotinamide in obesity-related heart failure with preserved ejection fraction
Mahmoud Abdellatif, Francisco Vasques‐Nóvoa, Viktoria Trummer-Herbst, Sylvère Durand, Franziska Koser, Moydul Islam, Jihoon Nah, Eun‐Ah Sung, Ruli Feng, Fanny Aprahamian, Andreas Prokesch, Andreas Prokesch, Junichi Sadoshima, Abhinav Diwan, Wolfgang A. Linke, João Pedro Ferreira, Guido Guido Kroemer, Simon Sedej (2025). Autophagy is required for the therapeutic effects of the NAD+ precursor nicotinamide in obesity-related heart failure with preserved ejection fraction. , DOI: https://doi.org/10.1093/eurheartj/ehaf062.
Article140 days agoMetabolites as agents and targets for cancer immunotherapy
Marcel P. Trefny, Guido Guido Kroemer, Laurence Zitvogel, Sebastian Kobold (2025). Metabolites as agents and targets for cancer immunotherapy . , DOI: https://doi.org/10.1038/s41573-025-01227-z.
Article140 days agoLysosomal membrane permeabilization enhances the anticancer effects of RNA Polymerase I transcription inhibitors
Lucille Ferret, Jonathan Pol, Allan Sauvat, Gautier Stoll, Karla Alvarez-Valadez, Alexandra Müller, Julie Le Naour, F. Peyre, Gerasimos Anagnostopoulos, Isabel Martins, Maria Chiara Maiuri, Harald Wodrich, Lionel Guittat, Jean‐Louis Mergny, Guido Guido Kroemer, Mojgan Djavaheri‐Mergny (2025). Lysosomal membrane permeabilization enhances the anticancer effects of RNA Polymerase I transcription inhibitors. , DOI: https://doi.org/10.1101/2025.03.03.641132.
Preprint140 days agoPotent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin
Giulia Cerrato, Allan Sauvat, Mahmoud Abdellatif, Guido Guido Kroemer (2025). Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin. , 14(1), DOI: https://doi.org/10.1080/2162402x.2025.2515176.
Article140 days agoImmunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates
Oliver Kepp, Guido Guido Kroemer (2025). Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates. , 14(1), DOI: https://doi.org/10.1080/2162402x.2025.2533488.
Article140 days ago